Genmab — September 2013
-
i gamle dage (før 08) sagde vi at fase 3 var 75% sandsynlighed. Jeg kan huske at jeg har set noget primary endpoint statiistik. Og det er ikke 75% der nå det. Men når man er kommet så langt i kræft så er det mere end 50% vil jeg tro.
-
-
ofatumumab in combination with bendamustine
is an effective and tolerable therapy, providing high response rates
and an acceptable safety profile for patients with either previously
untreated CLL who are inappropriate for fludarabine-based therapy,
or patients with relapsed CLL -
hvor kommer den poster fra?
-
jeg synes cr er rigtigt stærke
-
-
tak
-
Dobbelt op på CR ifht Rituximab http://www.ncbi.nlm.nih.gov/pubmed/22869884
-
er det ikke de data Jan sagde at GEN ville præsentere på iwcll i Køln? Det ser dælme godt ud!
-
JV, det er data fra ofa-bendamustine fase 2. De data han har lovet, men flyttet til ASH er ofa-clorambucil
-
Men samme indikation.
-
Hej MAds - der var oprindeligt to datasæt på iwcll - og ofa+chlorambucil fase III blev flyttet mens bendamustine blev på iwcll - som jeg husker det
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind